Miren Ettcheto

List of Publications by Year
in descending order

71 papers	3,413 citations	186265 28 h-index	144013 57 g-index
74 all docs	74 docs citations	74 times ranked	4896 citing authors

#	Article	IF	Citations
1	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. Nutritional Neuroscience, 2022, 25, 2627-2637.	3.1	1
2	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. International Journal of Pharmaceutics, 2022, 612, 121379.	5.2	15
3	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. Pharmaceutics, 2022, 14, 285.	4.5	15
4	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. Epilepsia Open, 2022, 7, .	2.4	14
5	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	10.9	26
6	Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics, 2022, 14, 90.	4.5	28
7	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. Molecular Medicine, 2022, 28, 48.	4.4	2
8	Therapeutic Strategies for Neurological Disorders: From Natural Compounds to Innovative Molecular Designs. Current Pharmaceutical Design, 2022, 28, i-ii.	1.9	0
9	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's Disease, 2021, 82, S127-S139.	2.6	7
10	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	2.6	13
11	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acidÂnanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine, 2021, 16, 19-35.	3.3	18
12	Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment. Pharmaceuticals, 2021, 14, 220.	3.8	8
13	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. Journal of Nanobiotechnology, 2021, 19, 122.	9.1	60
14	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. Applied Sciences (Switzerland), 2021, 11, 4305.	2.5	26
15	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APPswe/PS1dE9 mice. Cell and Bioscience, 2021, 11, 141.	4.8	7
16	Masitinib for the treatment of Alzheimer's disease. Neurodegenerative Disease Management, 2021, 11, 263-276.	2.2	14
17	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. Toxics, 2021, 9, 195.	3.7	11
18	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment. Pharmaceuticals, 2021, 14, 890.	3.8	19

#	Article	IF	Citations
19	Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells. International Journal of Molecular Sciences, 2021, 22, 9545.	4.1	2
20	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. Journal of Medicinal Chemistry, 2021, 64, 812-839.	6.4	45
21	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. Pharmaceuticals, 2021, 14, 1057.	3.8	27
22	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 255.	4.1	18
23	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Molecular Neurobiology, 2020, 57, 1814-1827.	4.0	51
24	Involvement of JNK1 in Neuronal Polarization During Brain Development. Cells, 2020, 9, 1897.	4.1	8
25	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. Journal of Nanobiotechnology, 2020, 18, 156.	9.1	38
26	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine, 2020, 15, 1239-1261.	3.3	68
27	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. Expert Opinion on Drug Discovery, 2020, 15, 993-1003.	5.0	5
28	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. Nanomaterials, 2020, 10, 292.	4.1	769
29	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. Nanomaterials, 2020, 10, 720.	4.1	44
30	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	1.9	12
31	JNK isoforms control mammal adult hippocampal neurogenesis. Mexican Journal of Medical Research ICSA, 2020, 8, 5-12.	0.2	1
32	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	3.4	40
33	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics, 2019, 11, 460.	4.5	115
34	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. Molecular Neurobiology, 2019, 56, 5856-5865.	4.0	20
35	Current Applications of Nanoemulsions in Cancer Therapeutics. Nanomaterials, 2019, 9, 821.	4.1	147
36	A metabolic perspective of late onset Alzheimer's disease. Pharmacological Research, 2019, 145, 104255.	7.1	19

#	Article	IF	Citations
37	Isoform‑selective as opposed to complete depletion of fibroblast growth factor 2 (FGF‑2) has no major impact on survival and gene expression in SOD1 G93A amyotrophic lateral sclerosis mice. European Journal of Neuroscience, 2019, 50, 3028-3045.	2.6	1
38	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	5.6	52
39	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, 2019, 301, 62-75.	9.9	207
40	Role of brain c‑Jun N‑terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high‑fat diet pre‑clinical model. Journal of Neurochemistry, 2019, 149, 255-268.	3.9	6
41	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine, 2019, 97, 1723-1733.	3.9	10
42	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. Expert Opinion on Investigational Drugs, 2019, 28, 93-97.	4.1	5
43	Characterizing the multiple roles of FGF‑2 in SOD1^{G93A} ALS mice in vivo and in vitro. Journal of Cellular Physiology, 2019, 234, 7395-7410.	4.1	9
44	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers in Aging Neuroscience, 2019, 11, 344.	3.4	35
45	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	3.0	2
46	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1073-1085.	3.3	60
47	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	4.0	24
48	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	2.6	150
49	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. Journal of Nanobiotechnology, 2018, 16, 32.	9.1	163
50	Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein. Neurología (English Edition), 2018, 33, 47-58.	0.4	46
51	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	4.0	21
52	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. Neuropharmacology, 2018, 131, 440-452.	4.1	28
53	Memantine‑Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. Small, 2018, 14, 1701808.	10.0	77
54	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	2.6	10

#	Article	IF	Citations
55	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. Pharmaceuticals, 2018, 11, 11.	3.8	45
56	Experimental Models for Aging and their Potential for Novel Drug Discovery. Current Neuropharmacology, 2018, 16, 1466-1483.	2.9	35
57	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-32.	0.0	0
58	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Redox Biology, 2017, 13, 345-352.	9.0	36
59	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. Pharmacological Reports, 2017, 69, 409-418.	3.3	15
60	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1171-1182.	3.3	64
61	Long-term exposition to a high fat diet favors the appearance of β-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer's disease. Mechanisms of Ageing and Development, 2017, 162, 38-45.	4.6	79
62	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Frontiers in Bioscience - Landmark, 2017, 22, 795-814.	3.0	19
63	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plasticity, 2016, 2016, 1-15.	2.2	200
64	Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice. Journal of Alzheimer's Disease, 2016, 54, 233-251.	2.6	46
65	PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen—in vitro, ex vivo and in vivo characterization. Colloids and Surfaces B: Biointerfaces, 2016, 145, 241-250.	5.0	108
66	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 6183-6193.	4.0	19
67	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. Molecular Neurobiology, 2015, 52, 120-129.	4.0	9
68	The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. Life Sciences, 2015, 140, 19-28.	4.3	34
69	Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. Experimental Gerontology, 2015, 65, 69-78.	2.8	19
70	Masitinib for the treatment of mild to moderate Alzheimer's disease. Expert Review of Neurotherapeutics, 2015, 15, 587-596.	2.8	63
71	Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations. Frontiers in Pharmacology, 0, 13, .	3.5	2